Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced that its Randomization, Trial Supply Management (RTSM) Software as a Service Business is partnering with IDDI to enable software delivery to their customer base.
New partnership will provide IDDI’s clients with a configurable, agile, purpose built RTSM system that accommodates simple to highly complex studies without custom code
RTSM supports rapid study start-up and provides the functionality required to meet the ever-increasing level of complexity of many clinical trials
Clario RTSM accommodates the full spectrum of protocol designs, from simple studies that require only randomization through complex studies that involve dosing, titration, and multiple cohorts
RTSM supports rapid study start-up and provides the functionality required to meet the ever-increasing level of complexity of many clinical trials. Clario offers the industry’s only purpose-built, end-to-end, configurable RTSM solution that reduces cost and increases speed of deployment. Together, Clario’s Interactive Response Technology (IRT) and Trial Supply Optimization (TSO) covers the full cycle of supply management from planning and forecasting, through inventory management.
“We are very excited that IDDI has chosen Clario RTSM to randomize and manage supply in their sponsors’ studies. Clario RTSM is configurable software, that allows analysts to configure studies rather than programmers. Combined with the integrated trial supply management software, IDDI will be able to deliver a perfectly managed supply plan in each study or program of studies. We are very pleased to support IDDI and their sponsors to optimize their clinical programs,” commented Guy Crossley, President of Clario eClinical Software.
“We chose Clario RTSM because it gives us the ability to help our sponsors in a way that no other software can. The configurable nature of the software will allow us to bring studies to market much faster than our competitors and will also allow us to manage mid-study changes more efficiently, with less effort. In addition, we will be able to continue combining our RTSM expertise with our statistical expertise to ensure that studies are configured in the most reliable and efficient way for our clients. We are thrilled with our strategic decision,” said Serge Bodart, Chief Commercial Officer at IDDI.